-
Pfizer (NYSE:PFE) Hasn’t Been This Cheap in 13 Years. Time to Buy?
09 May 2025 18:23 GMT
… and a diversified portfolio, Pfizer offers compelling value, but … Initiatives to Rebuild Growth
Pfizer is actively addressing these … upside.
Risks and Opportunities
Pfizer faces notable risks. Potential … just tariff risks, Pfizer faces a patent cliff for a …
-
Jim Cramer on Pfizer (PFE): “Trying Big Targets, but New Wins Still Elusive”
09 May 2025 05:37 GMT
… take a look at where Pfizer Inc. (NYSE:PFE) stands … ).
Story Continues Jim Cramer on Pfizer (PFE): "Trying Big Targets … on Pfizer Inc. (NYSE:PFE)’s inability to offset its patent expirations … after all sorts. Pfizer’s trying but Pfizer’s stock has not …
-
Pfizer Has Unreasonable Whiff Of The Marlboro Man
07 May 2025 07:00 GMT
… blood thinner Eliquis as patent protection expires, drawing in … the cigarette market shrivels.
Pfizer, meanwhile, continues to provide … unreasonable.
Context News
Pfizer said on April 29 that … unfavorable foreign exchange rates. Pfizer’s earnings were 52 …
-
3 Magnificent S&P 500 Dividend Stocks Down 30% to Buy and Hold Forever
10 May 2025 10:51 GMT
… ;s projected profit.
3. Pfizer
When a major pharmaceuticals company … key products are coming off patent, rivals have better alternatives, … Rick Munarriz has positions in Pfizer and Target. The Motley … positions in and recommends Pfizer and Target. The Motley …
-
New FDA Leadership Could Raise The Bar For Drug Approvals
09 May 2025 18:19 GMT
… signals: even talk of patent reform or aggressive generic … for companies like Moderna or Pfizer's partners).
… benefit companies like Moderna, Pfizer/BioNTech, and others … generics entry or limiting certain patent extension tactics, industry trade …
-
Ivarmacitinib ‘promising’ for atopic dermatitis not controlled with topical therapies
09 May 2025 17:33 GMT
… Therapeutics, Micreos, My-OR Diagnostics, Pfizer, Pierre-Fabre, Regeneron/Sanofi … . Lio also reports having a patent pending for a Theraplex product.
-
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
09 May 2025 14:31 GMT
… Novartis Pharmaceuticals Corporation, Apotex Inc., Pfizer Inc. are significant contributors to … generic alternatives. Notable drugs facing patent expiration include:
Abilify Maintaina ( … Johnson & Johnson, Merck KGaA, Pfizer Inc, Sanofi SA, AstraZeneca Plc …
-
Generic Pharmaceuticals Market Opportunities and Strategy Report 2024-2033 Featuring Key Players - Teva Pharmaceutical, Sandoz, Sun Pharmaceutical, Viatris, and Abbott Laboratories - ResearchAndMarkets.com
09 May 2025 15:46 GMT
… increased number of surgical procedures, patent expiration of drugs, and a … limited market access due to patent protections on branded drugs. Going …
Fiterman Pharma
Geropharm
Zentiva
Polpharma
Pfizer
GlaxoSmithKline
Antibiotice Iași
Amneal …
-
Precision Medicine Market Analysis Report 2024-2030: Emergence of Biobanks as a Cornerstone of Precision Medicine as the Market is Projected to Reach $469 Billion - ResearchAndMarkets.com
09 May 2025 15:09 GMT
… Collaborations and Partnerships
Industry Insights
Patent Analysis
Pipeline Analysis
Legal Requirements …
Pacific Biosciences of California, Inc.
Pfizer Inc.
QIAGEN N.V
Quest …
-
Protalix Biotherapeutics Reports First Quarter 2025 Financial And Business Results
09 May 2025 12:07 GMT
… . Protalix has licensed to Pfizer Inc. the worldwide development … , but not limited to, Pfizer and Chiesi; risks related to … supply of drug products to Pfizer; potential product liability risks, … the uncertainty of obtaining patents covering our products and …
About
© 1995-2025